Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Brief Summary: A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab
C: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
D: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab

Answer: C